Avadel Pharmaceuticals PLC (AVDL NASDAQ) stock market data APIs
$21.4767
0.02(0.1%)
as of December 26, 2025
Try our APIs with
free plan!
Avadel Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Prev. Close
21.4767
Open
21.5158
High
21.5702
Low
21.397
52 wk Range
6.38-23.57
Market Cap
2 119 M
P/E Ratio
0
Shares Outstanding
98 141 K
Revenue
249 M
EPS
0.0002
Beta
1.632
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Avadel Pharmaceuticals PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avadel Pharmaceuticals PLC data using free add-ons & libraries
Get Avadel Pharmaceuticals PLC Fundamental Data
Avadel Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 249 M
- EBITDA: 2 699 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avadel Pharmaceuticals PLC News
New
Regencell Bioscience is the top performing pharma stock YTD
[Heart Health Concept] Eoneren/E+ via Getty Images The S&P healthcare index (XLV [https://seekingalpha.com/symbol/XLV]) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, t...
Halper Sadeh LLC Encourages AVDL, CMA, KVUE Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
How Recent Deal Developments Are Reshaping The Avadel Pharmaceuticals Investment Story
Avadel Pharmaceuticals' fair value estimate has been nudged slightly lower to about $20.94 per share from roughly $21.06, even as the discount rate holds near 7.34 % and revenue growth expectations ho...
Announcement relating to despatch of Rule 15 proposal
Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGUL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
